For example, combining pembrolizumab with a synthetic CpG oligonucleotide TLR9 agonist, SD-101, exhibited greater clinical efficacy than PD-1 blockade alone in a phase Ib trial, which was associated with elevated tumor-infiltrating DC characteristics (140). Here, PDCD1 is linked to neoplasm.